Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Aging Cell ; 15(5): 872-84, 2016 10.
Article in English | MEDLINE | ID: mdl-27312235

ABSTRACT

The National Institute on Aging Interventions Testing Program (ITP) evaluates agents hypothesized to increase healthy lifespan in genetically heterogeneous mice. Each compound is tested in parallel at three sites, and all results are published. We report the effects of lifelong treatment of mice with four agents not previously tested: Protandim, fish oil, ursodeoxycholic acid (UDCA) and metformin - the latter with and without rapamycin, and two drugs previously examined: 17-α-estradiol and nordihydroguaiaretic acid (NDGA), at doses greater and less than used previously. 17-α-estradiol at a threefold higher dose robustly extended both median and maximal lifespan, but still only in males. The male-specific extension of median lifespan by NDGA was replicated at the original dose, and using doses threefold lower and higher. The effects of NDGA were dose dependent and male specific but without an effect on maximal lifespan. Protandim, a mixture of botanical extracts that activate Nrf2, extended median lifespan in males only. Metformin alone, at a dose of 0.1% in the diet, did not significantly extend lifespan. Metformin (0.1%) combined with rapamycin (14 ppm) robustly extended lifespan, suggestive of an added benefit, based on historical comparison with earlier studies of rapamycin given alone. The α-glucosidase inhibitor, acarbose, at a concentration previously tested (1000 ppm), significantly increased median longevity in males and 90th percentile lifespan in both sexes, even when treatment was started at 16 months. Neither fish oil nor UDCA extended lifespan. These results underscore the reproducibility of ITP longevity studies and illustrate the importance of identifying optimal doses in lifespan studies.


Subject(s)
Antioxidants/pharmacology , Estradiol/pharmacology , Glycoside Hydrolase Inhibitors/pharmacology , Longevity/drug effects , NF-E2-Related Factor 2/metabolism , alpha-Glucosidases/metabolism , Acarbose/pharmacology , Animals , Drugs, Chinese Herbal/pharmacology , Fish Oils/pharmacology , Hand Strength , Male , Masoprocol/pharmacology , Metformin/pharmacology , Mice , Rotarod Performance Test , Sirolimus/pharmacology , Survival Analysis , Ursodeoxycholic Acid/pharmacology
2.
J Gerontol A Biol Sci Med Sci ; 68(1): 6-16, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22451473

ABSTRACT

The National Institute on Aging Interventions Testing Program (ITP) was established to evaluate agents that are hypothesized to increase life span and/or health span in genetically heterogeneous mice. Each compound is tested in parallel at three test sites. It is the goal of the ITP to publish all results, negative or positive. We report here on the results of lifelong treatment of mice, beginning at 4 months of age, with each of five agents, that is, green tea extract (GTE), curcumin, oxaloacetic acid, medium-chain triglyceride oil, and resveratrol, on the life span of genetically heterogeneous mice. Each agent was administered beginning at 4 months of age. None of these five agents had a statistically significant effect on life span of male or female mice, by log-rank test, at the concentrations tested, although a secondary analysis suggested that GTE might diminish the risk of midlife deaths in females only.


Subject(s)
Curcumin/pharmacology , Longevity/drug effects , Oxaloacetic Acid/pharmacology , Stilbenes/pharmacology , Tea , Triglycerides/pharmacology , Age Factors , Aging/drug effects , Aging/pathology , Aging/physiology , Animals , Body Weight/drug effects , Drug Evaluation, Preclinical , Female , Longevity/genetics , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C3H , Mice, Inbred C57BL , Mice, Inbred DBA , Models, Animal , Motor Activity/drug effects , Pregnancy , Resveratrol , Sex Characteristics , Triglycerides/chemistry
3.
Aging Cell ; 6(4): 565-75, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17578509

ABSTRACT

The National Institute on Aging's Interventions Testing Program (ITP) has developed a plan to evaluate agents that are considered plausible candidates for delaying rates of aging. Key features include: (i) use of genetically heterogeneous mice (a standardized four-way cross), (ii) replication at three test sites (the Jackson Laboratory, TJL; University of Michigan, UM; and University of Texas, UT), (iii) sufficient statistical power to detect 10% changes in lifespan, (iv) tests for age-dependent changes in T cell subsets and physical activity, and (v) an annual solicitation for collaborators who wish to suggest new interventions for evaluation. Mice in the first cohort were exposed to one of four agents: aspirin, nitroflurbiprofen (NFP), 4-OH-alpha-phenyl-N-tert-butyl nitrone (4-OH-PBN), or nordihydroguiaretic acid (NDGA). An interim analysis was conducted using survival data available on the date at which at least 50% of the male control mice had died at each test site. Survival of control males was significantly higher, at the interim time-point, at UM than at UT or TJL; all three sites had similar survival of control females. Males in the NDGA group had significantly improved survival (P = 0.0004), with significant effects noted at TJL (P < 0.01) and UT (P < 0.04). None of the other agents altered survival, although there was a suggestion (P = 0.07) of a beneficial effect of aspirin in males. More data will be needed to determine if any of these compounds can extend maximal lifespan, but the current data show that NDGA reduces early life mortality risks in genetically heterogeneous mice at multiple test sites.


Subject(s)
Aging/drug effects , Aspirin/pharmacology , Cyclic N-Oxides/pharmacology , Flurbiprofen/analogs & derivatives , Masoprocol/pharmacology , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Antioxidants/pharmacology , Drug Evaluation, Preclinical , Female , Flurbiprofen/pharmacology , Male , Mice , Research Design , Survival Analysis
4.
Exp Biol Med (Maywood) ; 227(3): 201-7, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11856819

ABSTRACT

The aim of this study was to determine if long-term treatment with melatonin (MEL), a purported anti-aging agent, was as effective as calorie restriction (CR) in modulating immune parameters in aging Fischer 344 male rats. Splenic lymphocytes were isolated from 17-month-old rats that, beginning at 6 weeks of age, were treated with MEL (4 or 16 microg/ml in drinking water) and from 17-month-old rats fed ad libitum (AL) or rats fed a CR diet (55% of AL intake). The number of splenic T cell populations and T cell subsets was measured by flow cytometry, the proliferative response of splenocytes to Concanavalin A (Con A) and lipopolysaccharide (LPS) was measured by [(3)H]thymidine incorporation, and the induction of cytokine production (IL-2 and IFN-gamma) was measured by ELISA assay. In addition, the level of the natural killer (NK) cell activity was assessed by fluorimetric assay. CR rats had a higher number of lymphocytes expressing the naïve T cell marker (CD3 OX22) than AL rats (P < 0.05). CR rats also showed greater induction of proliferative response, IL-2 and IFN-gamma levels following Con A simulation, and NK cell activity than AL rats (P < 0.05). MEL-treated rats did not differ from AL rats in any of these parameters or in any other measurement. These results indicate that MEL treatment is unable to modulate immune function in a manner comparable with that of CR.


Subject(s)
Adjuvants, Immunologic/pharmacology , Aging/immunology , Immunity/drug effects , Melatonin/pharmacology , Aging/physiology , Animals , Diet , Energy Intake , Immunity/physiology , Melatonin/immunology , Rats , Rats, Inbred F344
SELECTION OF CITATIONS
SEARCH DETAIL